Boston Scientific price target raised to $66 from $63 at UBS

UBS raised the firm’s price target on Boston Scientific to $66 from $63 and keeps a Buy rating on the shares. Boston Scientific’s long-term guidance update was above expectations, with an otherwise usually conservative management team even more bullish than expected around major new product launches, the analyst tells investors in a research note. The firm is increasingly bullish that Boston Scientific can deliver upside to even this better than expected guidance raise, and interprets the 8%-10% as base case given this management team’s long track record of exercising prudent conservatism.